News

GJE Highly Recommended by IAM Patent 1000

We are delighted to be recognised as a top tier firm in the 2019 edition of IAM Patent 1000: The World’s Leading Patent Professionals. IAM undertook an exhaustive qualitative research project to identify outstanding firms and individuals across multiple jurisdictions. When identifying the leading firms, factors such as depth of...

Read more

Ligand Licenses VER250840 to Cumulus Oncology

Ligand Pharmaceuticals has announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialise VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and...

Read more

Closed Loop Medicine Raises £2.1M Pre-Series A

GJE client Closed Loop Medicine raised £2.1M in venture capital funding. The raise for the Cambridge-based health tech start-up was from Longwall Ventures Partners amongst other investment groups. Closed Loop Medicine is a start-up that helps doctors and healthcare providers deliver personalised treatment regimens by combining proven drug treatments with...

Read more

Stays may be available for computer simulation inventions at the EPO

Following on from our article commenting on the recent referral to the Enlarged Board of Appeal (G 1/19) the EPO have published a further notice concerning the staying of proceedings. The notice indicates that the President of the EPO has decided that all proceedings before the EPO in which the...

Read more

The President of the EPO is determined to prevent patents issuing directed to plants obtained by essentially biological processes

In a notice published yesterday, the President of the EPO has decided to stay any examination or opposition proceedings at the EPO where the patent application or patent in question claims a plant or animal exclusively obtained by means of an essentially biological process. This decision has been taken to...

Read more